Antigen News and Research

RSS

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Linear epitope mapping of the SARS-CoV-2 spike protein

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the primary target of many drug discovery efforts and is similarly utilized in each of the approved COVID-19 vaccines to elicit the generation of anti-spike protein antibodies, thereby granting immunity.

28 Mar 2021

A novel approach to oral vaccination against Covid-19

Scientists at the University of Würzburg together with a pharmaceutical company are working on a novel approach to oral vaccination against the coronavirus.

26 Mar 2021

New study may shed light on inflammatory bowel disease

Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.

26 Mar 2021

New screening method detects cancer biomarkers more effectively

Early screening can mean the difference between life and death in a cancer and disease diagnosis. That's why University of Central Florida researchers are working to develop a new screening technique that's more than 300 times as effective at detecting a biomarker for diseases like cancer than current methods.

26 Mar 2021

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

25 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

SARS-CoV-2 can cause persistent dendritic cell deficiencies

In a new study, the persistent influence of SARS-CoV-2 on dendritic cell deficiency seven months post-infection is asserted, and the mechanism of action investigated.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

Rapid antigen testing helps decrease the prevalence of SARS-CoV-2 in Slovakia

In Slovakia, in counties subject to two rounds of rapid antigen testing for SARS-CoV-2 where those who tested positive then isolated, the approach helped decrease the prevalence of positive tests by more than 50% in a week - all while primary schools and workplaces remained open.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Researchers in the United States have now demonstrated that T-cell receptor (TCR) sequencing might provide a reliable alternative to assessing infection in convalescent blood plasma, and may be applicable in the future for applying protective immunity to individuals.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

Study may help develop effective biosensors for non-invasive diagnosis of prostate cancer

The efficacy of biosensors used in clinical tests depends critically on the surface of the device on which the biorecognition molecules are immobilized.

23 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021

Engineering immunogens to focus immune response to SARS-CoV-2

Researchers have designed constructs by adding more glycans and adding the receptor-binding motif from related sarbecoviruses to focus the immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding motif. Such immunogens could potentially also neutralize other variants and coronaviruses.

18 Mar 2021